{"title":"血清总胆红素升高可能表明不稳定型心绞痛患者冠状动脉状况不佳","authors":"Qi Liang, Yongjian Zhang, Jin Liang","doi":"10.1155/2023/5532917","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Backgrounds</i>. Serum total bilirubin (STB) is recently more regarded as an antioxidant with vascular protective effects. However, we noticed that elevated STB appeared in unstable angina pectoris (UAP) patients with diffused coronary lesions. We aimed to explore STB’s roles in UAP patients, which have not been reported by articles. <i>Methods and Results</i>. 1120 UAP patients were retrospectively screened, and 296 patients were finally enrolled. They were grouped by Canadian Cardiovascular Society (CCS) angina grades. The synergy between PCI with TAXUS stent and cardiac surgery score (SYNTAX score) and corrected thrombolysis in myocardial infarction flow count (CTFC) were adopted to profile coronary features. The results showed that STB, mean platelet volume (MPV), hs-CRP, fasting blood glucose (FBG), red blood cell width (RDW), and CTFC elevated significantly in the CCS high-risk group. STB (<i>B</i> = 0.59, 95% CI: 0.39-0.74, <i>P</i> < 0.01) and MPV (<i>B</i> = 0.86, 95% CI: 0.42-1.31, <i>P</i> < 0.01) could indicate SYNTAX score changes for these patients. STB (≥21.7 <i>μ</i>mol/L) could even indicate a coronary slow flow condition (AUC: 0.88, 95% CI: 0.84-0.93, <i>P</i> < 0.01). Moreover, UAP patients with elevated STB had a lower event-free survival rate by the Kaplan-Meier curve. STB ≥21.7 <i>μ</i>mol/L could reflect a poor coronary flow status and indicate 1-year poor outcomes for these patients (HR: 2.01, 95% CI: 1.06-3.84, <i>P</i> < 0.01). <i>Conclusion</i>. Elevated STB in UAP patients has a close relationship with changes in SYNTAX score. STB (over 21.7 <i>μ</i>mol/L) could even indicate a coronary slow flow condition and poor outcomes for the UAP patients.</p>\n </div>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497366/pdf/","citationCount":"0","resultStr":"{\"title\":\"Elevated Serum Total Bilirubin Might Indicate Poor Coronary Conditions for Unstable Angina Pectoris Patients beyond as a Cardiovascular Protector\",\"authors\":\"Qi Liang, Yongjian Zhang, Jin Liang\",\"doi\":\"10.1155/2023/5532917\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Backgrounds</i>. Serum total bilirubin (STB) is recently more regarded as an antioxidant with vascular protective effects. However, we noticed that elevated STB appeared in unstable angina pectoris (UAP) patients with diffused coronary lesions. We aimed to explore STB’s roles in UAP patients, which have not been reported by articles. <i>Methods and Results</i>. 1120 UAP patients were retrospectively screened, and 296 patients were finally enrolled. They were grouped by Canadian Cardiovascular Society (CCS) angina grades. The synergy between PCI with TAXUS stent and cardiac surgery score (SYNTAX score) and corrected thrombolysis in myocardial infarction flow count (CTFC) were adopted to profile coronary features. The results showed that STB, mean platelet volume (MPV), hs-CRP, fasting blood glucose (FBG), red blood cell width (RDW), and CTFC elevated significantly in the CCS high-risk group. STB (<i>B</i> = 0.59, 95% CI: 0.39-0.74, <i>P</i> < 0.01) and MPV (<i>B</i> = 0.86, 95% CI: 0.42-1.31, <i>P</i> < 0.01) could indicate SYNTAX score changes for these patients. STB (≥21.7 <i>μ</i>mol/L) could even indicate a coronary slow flow condition (AUC: 0.88, 95% CI: 0.84-0.93, <i>P</i> < 0.01). Moreover, UAP patients with elevated STB had a lower event-free survival rate by the Kaplan-Meier curve. STB ≥21.7 <i>μ</i>mol/L could reflect a poor coronary flow status and indicate 1-year poor outcomes for these patients (HR: 2.01, 95% CI: 1.06-3.84, <i>P</i> < 0.01). <i>Conclusion</i>. Elevated STB in UAP patients has a close relationship with changes in SYNTAX score. STB (over 21.7 <i>μ</i>mol/L) could even indicate a coronary slow flow condition and poor outcomes for the UAP patients.</p>\\n </div>\",\"PeriodicalId\":9582,\"journal\":{\"name\":\"Cardiovascular Therapeutics\",\"volume\":\"2023 1\",\"pages\":\"\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2023-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497366/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2023/5532917\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2023/5532917","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
背景。血清总胆红素(STB)近年来越来越被认为是一种具有血管保护作用的抗氧化剂。然而,我们注意到STB升高出现在冠状动脉弥漫性病变的不稳定型心绞痛(UAP)患者。我们的目的是探讨STB在UAP患者中的作用,这方面尚未有文章报道。方法与结果:回顾性筛选1120例UAP患者,最终纳入296例患者。他们按照加拿大心血管学会(CCS)心绞痛分级进行分组。采用TAXUS支架PCI与心脏手术评分(SYNTAX评分)和校正后的心肌梗死血流计数(CTFC)之间的协同作用来描述冠状动脉特征。结果显示,CCS高危组STB、平均血小板体积(MPV)、hs-CRP、空腹血糖(FBG)、红细胞宽度(RDW)、CTFC均显著升高。STB (B = 0.59, 95% CI: 0.39-0.74, P <;0.01)和MPV (B = 0.86, 95% CI: 0.42-1.31, P <;0.01)可提示SYNTAX评分的变化。STB(≥21.7 μmol/L)甚至可以提示冠脉慢血流状态(AUC: 0.88, 95% CI: 0.84 ~ 0.93, P <;0.01)。此外,根据Kaplan-Meier曲线,STB升高的UAP患者无事件生存率较低。STB≥21.7 μmol/L,反映冠脉血流状态差,1年预后差(HR: 2.01, 95% CI: 1.06-3.84, P <;0.01)。结论。UAP患者STB升高与SYNTAX评分变化密切相关。STB(超过21.7 μmol/L)甚至可以提示冠状动脉慢血流状态和不良预后。
Elevated Serum Total Bilirubin Might Indicate Poor Coronary Conditions for Unstable Angina Pectoris Patients beyond as a Cardiovascular Protector
Backgrounds. Serum total bilirubin (STB) is recently more regarded as an antioxidant with vascular protective effects. However, we noticed that elevated STB appeared in unstable angina pectoris (UAP) patients with diffused coronary lesions. We aimed to explore STB’s roles in UAP patients, which have not been reported by articles. Methods and Results. 1120 UAP patients were retrospectively screened, and 296 patients were finally enrolled. They were grouped by Canadian Cardiovascular Society (CCS) angina grades. The synergy between PCI with TAXUS stent and cardiac surgery score (SYNTAX score) and corrected thrombolysis in myocardial infarction flow count (CTFC) were adopted to profile coronary features. The results showed that STB, mean platelet volume (MPV), hs-CRP, fasting blood glucose (FBG), red blood cell width (RDW), and CTFC elevated significantly in the CCS high-risk group. STB (B = 0.59, 95% CI: 0.39-0.74, P < 0.01) and MPV (B = 0.86, 95% CI: 0.42-1.31, P < 0.01) could indicate SYNTAX score changes for these patients. STB (≥21.7 μmol/L) could even indicate a coronary slow flow condition (AUC: 0.88, 95% CI: 0.84-0.93, P < 0.01). Moreover, UAP patients with elevated STB had a lower event-free survival rate by the Kaplan-Meier curve. STB ≥21.7 μmol/L could reflect a poor coronary flow status and indicate 1-year poor outcomes for these patients (HR: 2.01, 95% CI: 1.06-3.84, P < 0.01). Conclusion. Elevated STB in UAP patients has a close relationship with changes in SYNTAX score. STB (over 21.7 μmol/L) could even indicate a coronary slow flow condition and poor outcomes for the UAP patients.
期刊介绍:
Cardiovascular Therapeutics (formerly Cardiovascular Drug Reviews) is a peer-reviewed, Open Access journal that publishes original research and review articles focusing on cardiovascular and clinical pharmacology, as well as clinical trials of new cardiovascular therapies. Articles on translational research, pharmacogenomics and personalized medicine, device, gene and cell therapies, and pharmacoepidemiology are also encouraged.
Subject areas include (but are by no means limited to):
Acute coronary syndrome
Arrhythmias
Atherosclerosis
Basic cardiac electrophysiology
Cardiac catheterization
Cardiac remodeling
Coagulation and thrombosis
Diabetic cardiovascular disease
Heart failure (systolic HF, HFrEF, diastolic HF, HFpEF)
Hyperlipidemia
Hypertension
Ischemic heart disease
Vascular biology
Ventricular assist devices
Molecular cardio-biology
Myocardial regeneration
Lipoprotein metabolism
Radial artery access
Percutaneous coronary intervention
Transcatheter aortic and mitral valve replacement.